Drugs / DW6014
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05823883 | Jun → Jul 2023 | — | Dong Wha Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05823870 | Feb → Mar 2023 | — | Dong Wha Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DW6014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05823870 ↗ |
| Route | Oral | “Single oral administration of DW6014 after an overnight fast” NCT05823870 ↗ |